HRP20211810T1 - Liječenje i prevencija prehlade korištenjem povidon-joda - Google Patents
Liječenje i prevencija prehlade korištenjem povidon-joda Download PDFInfo
- Publication number
- HRP20211810T1 HRP20211810T1 HRP20211810TT HRP20211810T HRP20211810T1 HR P20211810 T1 HRP20211810 T1 HR P20211810T1 HR P20211810T T HRP20211810T T HR P20211810TT HR P20211810 T HRP20211810 T HR P20211810T HR P20211810 T1 HRP20211810 T1 HR P20211810T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- pharmaceutical composition
- cold
- pharmaceutical preparation
- human subject
- Prior art date
Links
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 title claims 5
- 201000009240 nasopharyngitis Diseases 0.000 title claims 5
- 229920000153 Povidone-iodine Polymers 0.000 title 1
- 229960001621 povidone-iodine Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 241000282414 Homo sapiens Species 0.000 claims 9
- 231100000676 disease causative agent Toxicity 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 5
- 239000002502 liposome Substances 0.000 claims 4
- 241000709661 Enterovirus Species 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- FAAHNQAYWKTLFD-UHFFFAOYSA-N 1-butan-2-ylpyrrolidin-2-one Chemical compound CCC(C)N1CCCC1=O FAAHNQAYWKTLFD-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 244000309467 Human Coronavirus Species 0.000 claims 1
- 241000711920 Human orthopneumovirus Species 0.000 claims 1
- 241000430519 Human rhinovirus sp. Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 241000351643 Metapneumovirus Species 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- -1 analgesic Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037921 secondary disease Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 206010041232 sneezing Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Farmaceutski pripravak koji sadrži povidon-jod (PVP-I) u koncentraciji većoj od 0,10% m/v i manjoj od oko 2,5% m/v i u kojem najmanje 50% PVP-I nije povezano s liposomima ili drugim čestičnim nosačima za upotrebu u liječenju prehlade, smanjenju simptoma prehlade, smanjenju trajanja prehlade kod ljudskog subjekta ili izbjegavanju prehlade kod ljudskog subjekta koji je bio izložen trećima sa simptomima prehlade pri čemu se farmaceutski pripravak nanosi na nosne prolaze ljudskog subjekta na sobnoj temperaturi i pri čemu je uzročnik ili potencijalni uzročnik prehlade virus koji nije virus gripe.
2. Farmaceutski pripravak koji sadrži povidon-jod (PVP-I) u koncentraciji većoj od 0,10% m/v i manjoj od oko 2,5% m/v i u kojem najmanje 50% PVP-I nije povezano s liposomima ili drugim čestičnim nosačima za uporabu u liječenju za smanjenje aktivnosti, održivosti ili broja virusa koji nisu virusi gripe unutar nosnih prolaza ljudskog subjekta, pri čemu su virusi uzročnici ili potencijalni uzročnici prehlada i farmaceutski pripravak se nanosi na nosne prolaze ljudskog subjekta na sobnoj temperaturi.
3. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, pri čemu liječenje smanjuje rizik, učestalost ili težinu sekundarne bolesti povezane s prehladom kod ljudskog subjekta, pri čemu se sekundarna bolest odabire iz skupine koju čine bronhitis, upala srednjeg uha i sinusitis i/ili smanjuje rizik, učestalost ili težinu bolesti donjeg dišnog sustava povezane s prehladom u ljudi koji pate od KOPB, astme, emfizema ili cistične fibroze, ili osobe s narušenim imunitetom.
4. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je koncentracija PVP-I u farmaceutskom pripravku koji se primjenjuje na nosne prolaze oko 0,1% do oko 1,0% m/v, poželjno oko 0,2% do oko 0,5% m/v, poželjno oko 0,2% do oko 0,45% m/v.
5. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu najmanje 70%, 80% ili 90% PVP-I nije povezano s liposomima ili drugim čestičnim nosačima.
6. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu farmaceutski pripravak ne sadrži liposome.
7. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu se farmaceutski pripravak primjenjuje u nosnice ljudskog subjekta, između 1 i 12 puta dnevno.
8. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu je između oko 0,05 mL i oko 1,0 mL farmaceutskog pripravka primijenjeno u svaku nosnicu ljudskog subjekta pri svakoj primjeni pripravka.
9. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu je uzročnik ili potencijalni uzročnik prehlade odabran iz skupine koju čine rinovirusi, humani koronavirusi, humani virusi parainfluence, humani respiratorni sincicijski virusi, adenovirusi, enterovirusi osim rinovirusa, metapneumovirusi i sve njihove kombinacije.
10. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu je uzročnik ili potencijalni uzročnik prehlade humani rinovirus.
11. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1, 3 do 10, pri čemu je simptom prehlade odabran iz skupine koju čine zimica, glavobolje, bolovi i tegobe, umor, curenje iz nosa, kihanje, kašalj, začepljenost nosa, grlobolja i njihove kombinacije.
12. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu je farmaceutski pripravak u obliku doziranja odabranom iz skupine koju čine intranazalne otopine, kapi, sprejevi, gelovi, aerosoli i inhalanti.
13. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 12, pri čemu farmaceutski pripravak nadalje sadrži najmanje jedno sredstvo odabrano iz skupine koju čine dekongestiv, antihistaminik, analgetik, antipiretik, protuupalno sredstvo, steroid, sredstvo za suzbijanje kašlja i ekspektorans.
14. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, pri čemu farmaceutski pripravak nadalje sadrži najmanje jedan farmaceutski prihvatljiv razrjeđivač, ekscipijent ili nosač.
15. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 14, pri čemu je razrjeđivač, ekscipijent ili nosač aroma, zaslađivač, bojilo, otapalo, pufer, alkohol, polimer, surfaktant ili drugi razrjeđivač ili ekscipijent dizajniran za optimiziranje nazalne dostave, intranazalne distribucije, stabilnosti, učinkovitosti, prihvatljivosti, podnošljivosti pripravka.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014206143A AU2014206143C1 (en) | 2014-07-23 | Treatment and prevention of the common cold using povidone-iodine | |
| EP18152155.0A EP3326635B1 (en) | 2014-07-23 | 2015-07-06 | Treatment and prevention of the common cold using povidone-iodine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211810T1 true HRP20211810T1 (hr) | 2022-03-04 |
Family
ID=51794584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211810TT HRP20211810T1 (hr) | 2014-07-23 | 2015-07-06 | Liječenje i prevencija prehlade korištenjem povidon-joda |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11000542B2 (hr) |
| EP (2) | EP3171881A4 (hr) |
| JP (2) | JP2017522330A (hr) |
| CN (1) | CN106794198A (hr) |
| AU (2) | AU2015292256B2 (hr) |
| CA (1) | CA2955982C (hr) |
| DK (1) | DK3326635T3 (hr) |
| ES (1) | ES2895429T3 (hr) |
| HK (1) | HK1249851A1 (hr) |
| HR (1) | HRP20211810T1 (hr) |
| HU (1) | HUE056533T2 (hr) |
| MY (1) | MY189342A (hr) |
| NZ (1) | NZ728284A (hr) |
| PH (1) | PH12017500135A1 (hr) |
| PL (1) | PL3326635T3 (hr) |
| PT (1) | PT3326635T (hr) |
| SG (2) | SG11201700286XA (hr) |
| WO (1) | WO2016011496A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016011496A1 (en) | 2014-07-23 | 2016-01-28 | Firebrick Pharma Pty Ltd | Treatment and prevention of the common cold using povidone-iodine |
| SG11202112735QA (en) * | 2019-06-10 | 2021-12-30 | Firebrick Pharma Ltd | Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes |
| CN114269354A (zh) * | 2019-08-30 | 2022-04-01 | 3M创新有限公司 | 应用消毒剂组合物进行病毒的传播预防 |
| CN113244262A (zh) * | 2020-02-07 | 2021-08-13 | 北京天衡军威医药技术开发有限公司 | 一种用于预防及治疗呼吸道感染性疾病的吸入粉雾制剂 |
| CN113244263A (zh) * | 2020-02-07 | 2021-08-13 | 北京天衡军威医药技术开发有限公司 | 一种用于预防及治疗呼吸道感染性疾病的雾化吸入制剂 |
| EP4240340A1 (en) * | 2020-11-09 | 2023-09-13 | Rucker Capital Advisors | Oral rinse, nasal spray and methods for prevention of covid-19 by lowering viral load of covid-19 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3028300A (en) | 1960-09-13 | 1962-04-03 | West Laboratories Inc | Germicidal compositions and methods for preparing the same |
| US5038769A (en) | 1983-06-29 | 1991-08-13 | Krauser Robert S | Method and apparatus for treating ailments |
| US4523589A (en) * | 1983-06-29 | 1985-06-18 | Krauser Robert S | Method and apparatus for treating ailments |
| US6171611B1 (en) | 1997-11-12 | 2001-01-09 | Dante J. Picciano | Iodine-containing nasal moisturizing saline and mouthwash solutions |
| JPH11228387A (ja) * | 1998-02-05 | 1999-08-24 | Taisho Pharmaceut Co Ltd | ヨード系殺菌剤を含有する薬用組成物 |
| AU747877B2 (en) | 1998-05-27 | 2002-05-30 | Euro-Celtique S.A. | Drug delivery system comprising a tightly compacted solid medicament stock |
| US7297344B1 (en) | 1999-05-27 | 2007-11-20 | Euro-Celtique, S.A. | Preparations for the promotion of wound healing in the upper respiratory tract and/or ear |
| US6694041B1 (en) | 2000-10-11 | 2004-02-17 | Digimarc Corporation | Halftone watermarking and related applications |
| US6696041B2 (en) * | 2002-03-20 | 2004-02-24 | Richard L. Hansen | Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use |
| US8679462B2 (en) | 2002-04-11 | 2014-03-25 | Saeed Rezakhany | Methods of preventing respiratory infections |
| JP2004352642A (ja) | 2003-05-29 | 2004-12-16 | Meiji Seika Kaisha Ltd | ウイルス感染症予防剤 |
| NZ545932A (en) * | 2003-08-28 | 2009-09-25 | Pure Bioscience | Anhydrous silver dihydrogen citrate compositions |
| DE602005009307D1 (de) * | 2004-10-13 | 2008-10-09 | Procter & Gamble | Vorrichtung zur Abgabe einer antimikrobiellen Zusammensetzung |
| RU2366460C2 (ru) * | 2004-12-09 | 2009-09-10 | Дзе Дайл Корпорэйшн | Композиции, имеющие высокую противовирусную и антибактериальную эффективность |
| EP1819229A2 (en) * | 2004-12-09 | 2007-08-22 | The Dial Corporation | Compositions having a high antiviral and antibacterial efficacy |
| US20060280809A1 (en) | 2005-06-14 | 2006-12-14 | Leshchiner Adele K | Anti-infective iodine based compositions for otic and nasal use |
| US8303994B2 (en) | 2006-06-22 | 2012-11-06 | Jack Howard Kessler | Method for the eradication of pathogens including S. aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells |
| WO2012177251A1 (en) * | 2011-06-22 | 2012-12-27 | Adeda Therapeutics Company Limited | Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases |
| CN103751274B (zh) | 2014-02-20 | 2016-08-17 | 河北旺达饲料兽药开发有限公司 | 一种治疗鸭、鹅黄病毒感染的药物组合物及其制备方法 |
| WO2016011496A1 (en) | 2014-07-23 | 2016-01-28 | Firebrick Pharma Pty Ltd | Treatment and prevention of the common cold using povidone-iodine |
| KR20170033925A (ko) | 2015-09-17 | 2017-03-28 | 송경진 | 항바이러스 및 세균용 스프레이 조성물 |
| KR101935250B1 (ko) | 2017-07-04 | 2019-01-04 | 김대황 | 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물 |
-
2015
- 2015-07-06 WO PCT/AU2015/050378 patent/WO2016011496A1/en active Application Filing
- 2015-07-06 ES ES18152155T patent/ES2895429T3/es active Active
- 2015-07-06 AU AU2015292256A patent/AU2015292256B2/en active Active
- 2015-07-06 PT PT181521550T patent/PT3326635T/pt unknown
- 2015-07-06 EP EP15824932.6A patent/EP3171881A4/en not_active Withdrawn
- 2015-07-06 US US15/327,998 patent/US11000542B2/en active Active
- 2015-07-06 EP EP18152155.0A patent/EP3326635B1/en active Active
- 2015-07-06 CA CA2955982A patent/CA2955982C/en active Active
- 2015-07-06 CN CN201580046383.9A patent/CN106794198A/zh active Pending
- 2015-07-06 MY MYPI2017700171A patent/MY189342A/en unknown
- 2015-07-06 NZ NZ728284A patent/NZ728284A/en unknown
- 2015-07-06 DK DK18152155.0T patent/DK3326635T3/da active
- 2015-07-06 SG SG11201700286XA patent/SG11201700286XA/en unknown
- 2015-07-06 JP JP2017503154A patent/JP2017522330A/ja active Pending
- 2015-07-06 SG SG10201900559VA patent/SG10201900559VA/en unknown
- 2015-07-06 PL PL18152155T patent/PL3326635T3/pl unknown
- 2015-07-06 HU HUE18152155A patent/HUE056533T2/hu unknown
- 2015-07-06 HR HRP20211810TT patent/HRP20211810T1/hr unknown
-
2017
- 2017-01-20 PH PH12017500135A patent/PH12017500135A1/en unknown
-
2018
- 2018-07-18 HK HK18109282.8A patent/HK1249851A1/zh unknown
-
2019
- 2019-05-01 AU AU2019100465A patent/AU2019100465B4/en not_active Expired
-
2020
- 2020-06-19 US US16/907,086 patent/US20200316109A1/en not_active Abandoned
- 2020-12-04 JP JP2020201805A patent/JP2021059553A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2955982A1 (en) | 2016-01-28 |
| AU2014206143B1 (en) | 2014-10-23 |
| US20170165296A1 (en) | 2017-06-15 |
| EP3326635A1 (en) | 2018-05-30 |
| HUE056533T2 (hu) | 2022-02-28 |
| AU2015292256A1 (en) | 2017-06-15 |
| WO2016011496A1 (en) | 2016-01-28 |
| AU2019100465B4 (en) | 2020-06-18 |
| NZ728284A (en) | 2020-07-31 |
| JP2017522330A (ja) | 2017-08-10 |
| HK1249851A1 (zh) | 2018-11-16 |
| PT3326635T (pt) | 2021-11-04 |
| ES2895429T3 (es) | 2022-02-21 |
| AU2015292256B2 (en) | 2020-09-17 |
| MY189342A (en) | 2022-02-04 |
| US20200316109A1 (en) | 2020-10-08 |
| PL3326635T3 (pl) | 2022-02-07 |
| PH12017500135B1 (en) | 2017-05-29 |
| CA2955982C (en) | 2023-09-05 |
| EP3171881A4 (en) | 2018-01-10 |
| JP2021059553A (ja) | 2021-04-15 |
| US11000542B2 (en) | 2021-05-11 |
| SG11201700286XA (en) | 2017-02-27 |
| CN106794198A (zh) | 2017-05-31 |
| AU2019100465A4 (en) | 2019-06-06 |
| SG10201900559VA (en) | 2019-02-27 |
| PH12017500135A1 (en) | 2017-05-29 |
| EP3326635B1 (en) | 2021-09-01 |
| EP3171881A1 (en) | 2017-05-31 |
| DK3326635T3 (da) | 2021-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211810T1 (hr) | Liječenje i prevencija prehlade korištenjem povidon-joda | |
| Velkov et al. | Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead | |
| US8709496B2 (en) | Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract | |
| Choi et al. | Quercetin 3‐rhamnoside exerts antiinfluenza A virus activity in mice | |
| AR076621A1 (es) | Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador | |
| JP2017502064A5 (hr) | ||
| JP5902628B2 (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| JP2015508780A5 (hr) | ||
| SI2968312T1 (en) | Combination of Medicines | |
| Mifsud et al. | Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy | |
| US11013687B1 (en) | Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2 | |
| García et al. | Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution | |
| US20220387455A1 (en) | Treatment of moderate to severe influenza | |
| Lai et al. | Combinations of 1, 8‐cineol and oseltamivir for the treatment of influenza virus A (H3N2) infection in mice | |
| KR20220158030A (ko) | 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온 | |
| Shin et al. | Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate | |
| WO2011047065A1 (en) | Recombinant human cc10 protein for treatment of influenza | |
| EP3517117A1 (en) | Medicament for prevention or treatment of rhinovirus infection | |
| US20130216574A1 (en) | Kit providing multiple unmet therapeutic effects | |
| JP2016504381A5 (hr) | ||
| HRP20221185T1 (hr) | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom | |
| US11642372B2 (en) | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses | |
| US20220096536A1 (en) | THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES | |
| US20220133786A1 (en) | THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. |